NIH Grants

Please see below for recently completed NIH grants:

  • NIH-NIDDK. 5-R01-DK-088114-A1. Effects of Recombinant Human Leptin in Nonalcoholic Fatty Liver Disease (NAFLD). This proposal will investigate the efficacy of recombinant leptin therapy in NASH and relative leptin deficiency against placebo for a period of one year. It will also evaluate long-term effects in patients who have been treated with recombinant leptin therapy in our pilot studies. February 5, 2011 to December 31, 2015 with NCX till February 28, 2017. Oral EA (PI), $1,250,000 total direct costs
  • NIH R21-DK-098776. Probing the Relevance of the “Counter-Inflammatory” Noncanonical IkB Kinases in Regulation of Human Metabolism: An Early Proof-of-Concept Study. This proposal focuses on a clinical proof of concept study to evaluate a novel hypothesis. We hypothesize that the noncanonical IkB kinases IKKe and TBK1 are “counterinflammatory” kinases that keep inflammatory pathways in check while helping to support a positive energy balance. The overarching goal of this proposal is to develop a novel therapy for treatment of Type 2 diabetes. September 18, 2013 to July 31, 2015 with NCX until July 31, 2016. Oral EA (PI), $415,334 total direct costs
  • NIH-NIDDK. RO3- DK092542-01A1 Role of Lipid Intermediates in the Limited Human Adipose Tissue Expandability Associated with Obesity Induced Insulin Resistance. This project evaluates the profiles and functions of lipid intermediates in clinical phenotypes associated with insulin resistance and obesity. September 15, 2012 to September 20, 2013. Oral EA (Sub-contract PI from U Mississippi), $566,000 total direct costs